Reuters: Hot Stocks: BRIEF-Sarepta Therapeutics jumps in premarket after eteplirsen drug trial results

Reuters: Hot Stocks Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

BRIEF-Sarepta Therapeutics jumps in premarket after eteplirsen drug trial results Oct 3rd 2012, 11:55 NEW YORK | Wed Oct 3, 2012 7:55am EDT NEW YORK Oct 3 (Reuters) - Sarepta Therapeutics Inc : * Jumps 129.2 percent to $34.35 premarket after Duchenne Muscular Dystrophy drug eteplirsen trial results

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions